Johanne Chambers's lobbying: the clients they represent and every meeting they've reported since November 2021.
← LobbyingConsultant lobbyist
3Sixty Public Affairs Inc.
Former public offices
Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.
Federally-funded public drug plans, with respect to reimbursement for medicines for federal plan beneficiaries.
Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases.
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Implementation of Canada's action plan for pain and federal initiatives related to pain management.
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
Establish Innovation, Science and Economic Development Canada policies related to research and development of treatments for rare disorders
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs.
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
BudgetHealthIndustry
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
Economic DevelopmentHealthIndustryIntellectual PropertyRegional DevelopmentScience and TechnologyTaxation and Finance
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.